KRAS and non-small cell lung carcinoma: For NRF2 activation, it is important to consider that other mutated genes that contribute to NSCLC development (EGFR, TP53, KRAS, PTEN and PIK3CA) [135,148] correlate with particular NFE2L2/KEAP1 mutations.